Reproductive cancer is any cancer that starts in the organs of the reproductive system. In women, that includes five main types: cervical, ovarian, uterine, vaginal, and vulvar cancer. In men, the most common are prostate, testicular, and penile cancer. These cancers vary widely in how common they are, how they’re detected, and how they behave, but they share a connection to the organs involved in fertility and sexual health.
Gynecologic Cancers
The five gynecologic cancers are named for the organ where they begin. Cervical cancer starts in the cervix, the narrow lower end of the uterus. Ovarian cancer starts in the ovaries (and sometimes in the fallopian tubes). Uterine cancer, the most common gynecologic cancer globally with over 420,000 new cases per year, starts in the lining of the uterus. Vaginal cancer starts in the canal between the uterus and the outside of the body, and vulvar cancer starts in the external genital tissue.
Uterine cancer cases are projected to climb to 676,000 per year by 2050, driven largely by rising rates of obesity in high-income countries. Ovarian cancer is less common, with roughly 20,890 new cases expected in the U.S. in 2025, but it carries a higher death rate because it’s harder to catch early. Vaginal and vulvar cancers are the rarest of the five.
Male Reproductive Cancers
Prostate cancer is by far the most common reproductive cancer in men and one of the most commonly diagnosed cancers overall. It begins in the prostate gland, which surrounds the tube that empties the bladder. Testicular cancer starts in one or both testes and tends to affect younger men, typically between ages 15 and 44. Penile cancer is rare and begins in the skin or tissues of the penis.
Symptoms and Warning Signs
Abnormal vaginal bleeding or discharge is the single most shared warning sign across gynecologic cancers. It shows up in cervical, ovarian, uterine, and vaginal cancers. Any bleeding after menopause, between periods, or after sex deserves prompt attention.
Ovarian cancer has a reputation for being “silent,” but it does produce symptoms. Feeling full quickly, bloating, abdominal or back pain, and needing to urinate more often are all common. The issue is that these overlap with everyday digestive complaints, so they’re easy to dismiss. If they’re new and persist for more than two weeks, that pattern matters. Uterine cancer often shows up as unexpected bleeding, while vaginal cancer can also cause urinary urgency or constipation.
Vulvar cancer is the outlier. Rather than bleeding, it typically causes itching, burning, pain, or tenderness of the vulva, along with visible changes like a rash, sores, or warts.
For men, a painless lump or swelling in a testicle is the hallmark of testicular cancer. Prostate cancer in its early stages often causes no symptoms at all, which is why screening plays such a large role in detection.
What Causes Reproductive Cancer
Like all cancers, reproductive cancers develop when genes controlling cell growth pick up enough mutations to let cells divide unchecked. Those mutations can be inherited, acquired over a lifetime, or both. Some people carry inherited mutations in genes like BRCA1 or BRCA2 that sharply increase the risk of ovarian cancer and, to a lesser degree, other reproductive cancers.
HPV (human papillomavirus) is the single biggest environmental driver. High-risk strains of HPV, particularly types 16 and 18, cause roughly 70% of cervical cancers worldwide, and six additional strains account for another 20%. Up to 90% of vaginal cancers and about 50% of vulvar cancers are also HPV-related. In men, HPV increases the risk of penile cancer. The virus is transmitted through sexual and nonsexual contact, and most infections clear on their own. The danger comes when the infection persists long enough to trigger lasting genetic damage in cells.
Other established risk factors vary by cancer type. Smoking increases the risk of cervical and ovarian cancer. Obesity and certain hormone therapies raise the risk of uterine cancer. Asbestos exposure has sufficient evidence linking it to ovarian cancer. HIV co-infection makes HPV more likely to progress to cancer. For uterine cancer specifically, estrogen-based menopausal therapy is a recognized carcinogen.
HPV Vaccination and Prevention
The HPV vaccine is one of the most effective cancer-prevention tools available. Since its introduction in 2006, cervical precancer rates among screened women aged 18 to 20 dropped by 50%, and rates among women aged 21 to 24 dropped by 36%, comparing data from 2014-2015 to 2008-2009. The percentage of cervical lesions caused by vaccine-targeted HPV types has fallen 40% in vaccinated women.
Data from Sweden and Denmark show that women vaccinated as teenagers have lower rates of actual cervical cancer as adults, not just precancerous changes. The vaccine is recommended for preteens and teens of all genders, and it protects against the HPV strains responsible for cervical, vaginal, vulvar, and penile cancers. Vaccination works best before any HPV exposure, which is why it’s given at age 11 or 12, though catch-up vaccination is available through age 26 for most people.
Screening and Early Detection
Cervical cancer is the only gynecologic cancer with a widely available, effective screening test. Current guidelines recommend that women aged 30 to 65 get a primary HPV test every five years (the preferred option) or a combination of HPV testing and a Pap smear every five years. If HPV testing isn’t available, a Pap smear alone every three years is an alternative. Self-collected HPV testing has also been recognized as an appropriate screening method for average-risk women in this age group.
There is no reliable screening test for ovarian, vaginal, or vulvar cancer, which is why recognizing symptoms matters. Prostate cancer screening with a PSA blood test is available for men and is typically discussed with a doctor starting around age 50, or earlier for those at higher risk. Testicular cancer has no standard screening either, but self-exams can help men notice changes early.
How Survival Rates Vary by Stage
Stage at diagnosis is the single biggest factor in survival for most reproductive cancers. Ovarian cancer illustrates this dramatically. When the most common type (invasive epithelial) is caught while still localized to the ovaries, the five-year survival rate is 92%. Once it has spread to distant organs like the liver or lungs, that number drops to 32%.
Rarer ovarian subtypes fare somewhat better. Stromal tumors have a 96% five-year survival rate when localized and 75% even at advanced stages. Germ cell tumors of the ovary reach 98% when localized and 76% when distant. Fallopian tube cancer follows a similar pattern: 92% localized, 40% distant.
Testicular cancer is an outlier in the best possible way. Even when diagnosed at advanced stages, cure rates are high, making it one of the most treatable cancers overall. Prostate cancer detected early also has very high survival rates, with most men living well beyond ten years after diagnosis.
Treatment Approaches
Treatment for reproductive cancers depends on the type, stage, and specific molecular features of the tumor. Surgery to remove the cancer is the starting point for most. In ovarian cancer, this means removing as much tumor as possible, followed by chemotherapy. Women with inherited BRCA mutations or certain DNA repair deficiencies may receive a class of drugs called PARP inhibitors as ongoing maintenance therapy, which has significantly improved survival for this group.
Immunotherapy has become a major part of treatment for several reproductive cancers. In cervical cancer, adding immunotherapy to standard chemotherapy improved median survival from 14 months to over 18 months in clinical trials. In uterine cancer, immunotherapy is now a standard option, particularly for tumors with a specific molecular feature (mismatch repair deficiency) that makes them especially responsive.
Targeted therapies are also expanding. For uterine cancers that express certain proteins, antibody-drug conjugates deliver chemotherapy directly to cancer cells while sparing healthy tissue. Hormone-based treatments using drugs that block estrogen are being used for certain uterine cancers, sometimes combined with other targeted agents. For men, prostate cancer treatment ranges from active surveillance for slow-growing tumors to surgery, radiation, and hormone therapy that blocks testosterone from fueling cancer growth. Testicular cancer responds exceptionally well to a combination of surgery and chemotherapy.